SELL and neoplasm: In the case of patient-derived peripheral blood, several studies have shown that initial selection of PD-1+ and/or antigen-experienced (CD45RO+CD62L+, CD45RO+CD62L-, or CD45RO-CD62L-) T cells can further enhance in vitro enrichment of tumor-specific T cells (82, 83, 85–87).